Finanzas de Pulse Biosciences Inc (PLSE)PLSEPulse Biosciences Inc

Pulse Biosciences Inc (PLSE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Systems, accounting for 78.9% of total sales, equivalent to $209.00K. Another important revenue stream is Cycle units. Understanding this composition is critical for investors evaluating how PLSE navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Pulse Biosciences Inc maintains a gross margin of 37.10%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5823.04%, while the net margin is -5681.34%. These profitability ratios, combined with a Return on Equity (ROE) of -78.49%, provide a clear picture of how effectively PLSE converts its operational activities into shareholder value.

In the context of the broader market, PLSE competes directly with industry leaders such as CDNA and VCYT. With a market capitalization of $3.84B, it holds a leading position in the sector. When comparing efficiency, PLSE's gross margin of 37.10% stands against CDNA's 73.50% and VCYT's 71.93%. Such benchmarking helps identify whether Pulse Biosciences Inc is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin improvement to 37.10% in Q2 2026, but it still reported a net loss of $24,657,000 in the same quarter. Total revenue for Q2 2026 was $434,000, indicating early-stage commercial challenges.